In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AstraZeneca takes on Targacept's cognitive disorder candidate; deal ends

Executive Summary

AstraZeneca has licensed exclusive worldwide development and commercialization rights to Targacept's (central nervous system therapeutics) TC1734 (ispronicline) to treat Alzheimer's disease, schizophrenia, and other cognitive disorders. Targacept retains the option to co-promote the compound and any others that arise from the collaboration.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies